Sangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company's stock.

Other equities research analysts have also issued research reports about the stock. Barclays reduced their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Royal Bank Of Canada reissued a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Finally, Wall Street Zen lowered Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Hold" and an average price target of $4.50.

Sangamo Therapeutics Stock Down 2.7%

Shares of Sangamo Therapeutics stock traded down $0.02 on Tuesday, hitting $0.54. 3,037,400 shares of the company traded hands, compared to its average volume of 9,061,991. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company has a market cap of $126.38 million, a PE ratio of -1.39 and a beta of 1.19. The company has a 50-day moving average price of $0.57 and a 200 day moving average price of $0.99.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analysts' expectations of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. Equities research analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. E Fund Management Co. Ltd. acquired a new position in Sangamo Therapeutics during the 4th quarter valued at $25,000. JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 21,793 shares during the period. PNC Financial Services Group Inc. grew its position in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 25,000 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter valued at about $28,000. Finally, Captrust Financial Advisors acquired a new position in Sangamo Therapeutics in the 4th quarter valued at approximately $30,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.